ClearPoint Neuro Inc.
As of Oct 22, 2026, ClearPoint Neuro is in Stage 3, the topping phase, now in week 7 (since Sep 10, 2026). It closed at $9.25, 65.7% below its 52-week high and below its 200-day average, which is falling.
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CLPT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CLPT among Medical Devices97th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …97 | CLPT | Stage 3 · wk 7 | 18 | −38.2% |
ClearPoint Neuro: quick answers
What stage is ClearPoint Neuro in?
As of Oct 22, 2026, ClearPoint Neuro (CLPT) is in Stage 3, the topping phase. It entered Stage 3 on Sep 10, 2026 and is in week 7. What the four stages mean
Is ClearPoint Neuro in an uptrend?
Its uptrend has stalled. ClearPoint Neuro is in Stage 3, the topping phase that follows an advance. It trades 29.5% below its 200-day average, which is falling.
How far is ClearPoint Neuro from its 52-week high?
ClearPoint Neuro closed at $9.25 on Oct 22, 2026, 65.7% below its 52-week high of $26.98. Its 52-week low is $8.66.
How has ClearPoint Neuro performed over the past year?
As of Oct 22, 2026, ClearPoint Neuro is down 63.0% over the past year and down 34.1% so far in 2026.
Which sector and industry is ClearPoint Neuro in?
ClearPoint Neuro is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.